Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting took place in Washington, D.C. and virtually from 13-15 October 2021. The world’s largest meeting dedicated solely to cancer immunotherapy brought together stakeholders across the field to share research breakthroughs and educational updates to improve outcomes for cancer patients.
VJOncology caught up with the presenters on new research studies and clinical trials!
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
The Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting took place in Washington, D.C. and virtually from 13-15 October 2021. The world’s largest meeting dedicated solely to cancer immunotherapy brought together stakeholders across the field to share research breakthroughs and educational updates to improve outcomes for cancer patients.
VJOncology caught up with the presenters on new research studies and clinical trials!
@drenriquegrande discusses implications of the findings from the EV-302 trial (NCT04223856) of #enfortumab vedotin, an #ADC & #pembrolizumab in patients with locally advanced or metastatic #urothelialcancer 🔦
🎥@docchristoffer highlights the promising immunotherapeutic landscape for melanoma, discussing the INTerpath-001 trial's combinatory approach with neoantigen therapies and pembrolizumab:
🎥@MarianaBrandao0 of @JulesBordet highlights the multifaceted considerations in defining operability for #NSCLC, shedding light on the challenges posed by stage III disease:
Breast Cancer Sessions: Highlights from SABCS 2021
Join Lisa A. Carey (UNC Lineberger, Chapel Hill, NC) and Aleix Prat (Hospital Clínic Barcelona, Barcelona, Spain) as they discuss the latest advances in breast cancer presented at the San Antonio Breast Cancer Symposium (SABCS) 2021 and what the latest research means for the clinic.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.